Journal article

Cross talk between human regulatory T cells and antigen-presenting cells: Lessons for clinical applications

CM Wardell, KN MacDonald, MK Levings, L Cook

European Journal of Immunology | WILEY | Published : 2021

Abstract

Regulatory T cells (Tregs) have a critical role in maintaining self-tolerance and immune homeostasis. There is much interest in using Tregs as a cell therapy to re-establish tolerance in conditions such as inflammatory bowel disease and type 1 diabetes, with many ongoing clinical studies testing the safety and efficacy of this approach. Manufacturing of Tregs for therapy typically involves ex vivo expansion to obtain sufficient cell numbers for infusion and comes with the risk of altering the activity of key biological processes. However, this process also offers an opportunity to tailor Treg function to maximize in vivo activity. In this review, we focus on the roles of antigen-presenting c..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Bristol-Myers Squibb Canada


Funding Acknowledgements

The authors' own work in this area is supported by a grant from the Canadian Institutes for Health Research (FDN-154304). CMW is supported by a salary award from the BC Children's Hospital Research Institute. KNM is supported by a salary award from the Canadian Institutes for Health Research. MKL and LC receive salary awards from the BC Children's Hospital Research Institute. MKL has received research funding from Sangamo Therapeutics (formerly TxCell SA), Takeda, Bristol Myers Squibb, Pfizer and CRISPR Therapeutics and holds provisional patents relating to use of CARs in Tregs.